This Article Full Text Full Text (PDF) Erratum (v20,p4727) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freedman, G. M. Articles by Nicoloau, N. Search for Related Content PubMed PubMed Citation Articles by Freedman, G. M. Articles by Nicoloau, N.

Recursive Partitioning Identifies Patients at High and Low Risk for Ipsilateral Tumor Recurrence After Breast-Conserving Surgery and Radiation

From the Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA.

Address reprint requests to Gary M. Freedman, MD, Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Ave, Philadelphia, PA 19111; email: g_freedman{at}fccc.edu

PURPOSE: Recursive partitioning analysis (RPA), a method of building decision trees of significant prognostic factors for outcome, was used to determine subgroups at significantly different risk for ipsilateral breast tumor recurrence (IBTR) in early-stage breast cancer.

PATIENTS AND METHODS: Nine hundred twelve women underwent breast-conserving surgery, axillary dissection, and radiation. Systemic therapy was chemotherapy with or without tamoxifen in 32%, tamoxifen in 27%, or none in 41%. RPA was used to create a decision tree according to predictive variables that classify patients by IBTR risk, and the Kaplan-Meier method was used to calculate 10-year risks. Median follow-up was 5.9 years.

RESULTS: Age was the first split in the partition tree. Patients more than 55 years old had a 4% 10-year IBTR, the only further division being use of tamoxifen or not (2% v 5%, P = .03). For patients 55 years old, extensive intraductal component (EIC) was the next significant split. For EIC-negative tumors, age 35 years and negative margins were associated with a 10-year IBTR of 3%; with close ( 2 mm) or positive margins, 34%. Patients 36 to 55 years old with estrogen receptor–positive tumors receiving tamoxifen had a risk of IBTR of 5%, but had a 20% risk without tamoxifen.

CONCLUSION: This RPA showed that age 55 versus more than 55 years was the most significant factor for IBTR. Patients 35 years old had a low risk of IBTR when tumors were EIC-negative with negative margins. EIC was an independent factor for IBTR for ages 55 years. Use of tamoxifen was the most significant factor for patients older than 55 years, but it resulted in a greater absolute decrease in risk of IBTR for patients 36 to 55 years old.

Abstract presented at the Thirty-Seventh Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May 12-15, 2001.

This article has been cited by other articles:

				S. H. Yang, K. H. Yang, Y. P. Li, Y. C. Zhang, X. D. He, A. L. Song, J. H. Tian, L. Jiang, Z. G. Bai, L. F. He, et al. Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials Ann. Onc., June 1, 2008; 19(6): 1039 - 1044. [Abstract] [Full Text] [PDF]

				A. W. Fyles, D. R. McCready, L. A. Manchul, M. E. Trudeau, P. Merante, M. Pintilie, L. M. Weir, and I. A. Olivotto Tamoxifen with or without Breast Irradiation in Women 50 Years of Age or Older with Early Breast Cancer N. Engl. J. Med., September 2, 2004; 351(10): 963 - 970. [Abstract] [Full Text] [PDF]

				A. Hirsch Integrative Tumor Board: Recurrent Breast Cancer or New Primary? Integr Cancer Ther, September 1, 2003; 2(3): 272 - 276. [PDF]

				D. H. Roukos, A. M. Kappas, and N. J. Agnantis Perspectives and Risks of Breast-Conservation Therapy for Breast Cancer Ann. Surg. Oncol., August 1, 2003; 10(7): 718 - 721. [Full Text] [PDF]